Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness

American Journal of Transplantation

Volumn 9, Issue 9, 2009, Pages 2085-2091

  Cadena, J ^a   Levine, D J ^b   Angel, L F ^b   Maxwell, P R ^c   Brady, R ^c   Sanchez, J F ^b   Michalek, J E ^b   Levine, S M ^b   Restrepo, M I ^b,d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY HEALTH SYSTEM   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Aspergillus; Itraconazole; Lung transplantation; Prophylaxis; Voriconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

AGED; ANTIFUNGAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; ITRACONAZOLE; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; POSTOPERATIVE COMPLICATIONS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 69149096653     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02734.x     Document Type: Article

References (40)

1. Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: A review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 2004 24 : 674 685.
2. Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006 25 : 745 755.
3. The Organ Procuremet and Transplantation Network. Transplant: Transplant Year (2006-2007) by age type. Available from : http//www.optn.org/latestData/ rptData.asp. Accessed December 7, 2008.
4. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001 3 : 128 137.
5. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002 4 (Suppl 3 24 31.
6. Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003 22 : 258 266.
7. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004 3 CD004291.
8. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004 23 : 1376 1381.
9. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006 8 : 213 218.
10. Levine SM, Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest 2004 125 : 1224 1238.
11. Shitrit D, Ollech JE, Ollech A et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): Efficacy and drug interaction. J Heart Lung Transplant 2005 24 : 2148 2152.
12. Minari A, Husni R, Avery RK et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002 4 : 195 200.
13. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999 1 : 229 236.
14. Calvo V, Borro JM, Morales P et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999 115 : 1301 1304.
15. Borro JM, Solé A, de la Torre M et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008 40 : 3090 3093.
16. Solé A, Morant P, Salavert M, Pemán J, Morales P. Aspergillus infections in lung transplant recipients: Risk factors and outcome. Clin Microbiol Infect 2005 11 : 359 365.
17. Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006 6 : 3008 3016. (Pubitemid 44777932)
18. Fungal infections. Am J Transplant 2004 4 (Suppl 10 110 134.
19. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature. Chest 2001 119 : 169 175.
20. Mattner F, Weissbrodt H, Strueber M. Two case reports: Fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004 36 : 312 314.
21. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999 13 : 180 186.
22. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415. (Pubitemid 34851833)
23. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 360.
24. Mattner F, Chaberny IF, Weissbrodt H et al. Surveillance of invasive mold infections in lung transplant recipients: Effect of antimycotic prophylaxis with Itraconzole and voriconazole. Mycoses 2005 48 (Suppl 1 51 55.
25. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) Based on a European/North American Multicenter Study. JAMA 1993 270 : 2957 2963.
26. VFEND IV VFEND Tablets VFEND for Oral Suspension. Available from : http://www.fda.gov/cder/foi/label/2006/021266s18,021267s19,021630s10lbl.pdf. Accessed November 2008.
27. DRUGDEX® System [Internet database]. Available from : http://www.micromedex.com/about-us/legal/cite/#ama. Accessed September 10, 2006.
28. Forrest E. Hepatic disorders. In : Lee A, ed. Adverse Drug Reactions, 2nd Ed. Chicago, IL : Pharmaceutical Press, 2006 : 193 216.
29. MacLaren R. Hepatic and cholestatic diseases. In : Tisdale JE, Miller DA, eds. Drug-Induced Diseases: Prevention, Detection, and Management. Bethesda, MD : American Society of Health System Pharmacists, 2005 : 515 535.
30. Ascioglu S, Rex J H, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002 34 : 7 14.
31. Bag R. Fungal pneumonias in transplant recipients. Curr Opin Pulm Med 2003 9 : 193 198.
32. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007 45 : 305 320.
33. Capitano B, Potoski BA, Husain S et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrobial Agents Chemother 2006 50 : 1878 1880.
34. Muijsers RBR, Goa KL, Scott LJ. Voriconazole: In the treatment of invasive aspergillosis. Drugs 2002 62 : 2655 2664.
35. Prentice AG, Glasmacher A. Making sense of itraconzole pharmacokinetics. J Antimicrob Chemother 2005 56 (Suppl 1 i17 i22.
36. Patterson JE, Peters J, Calhoon JH et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000 2 : 22 28.
37. ® (Itraconazole) Capsules. Available from : http://www.fda.gov/medwatch/SAFETY/2001/sporanox
38. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 1572.
39. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007 39 : 425 429.
40. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005 191 : 1350 1360.